BR112013025222B8 - composição farmacêutica anti-hipertensiva e uso da mesma - Google Patents
composição farmacêutica anti-hipertensiva e uso da mesma Download PDFInfo
- Publication number
- BR112013025222B8 BR112013025222B8 BR112013025222A BR112013025222A BR112013025222B8 BR 112013025222 B8 BR112013025222 B8 BR 112013025222B8 BR 112013025222 A BR112013025222 A BR 112013025222A BR 112013025222 A BR112013025222 A BR 112013025222A BR 112013025222 B8 BR112013025222 B8 BR 112013025222B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- antihypertensive pharmaceutical
- hydrate
- pharmaceutically acceptable
- antihypertensive
- Prior art date
Links
- 230000003276 anti-hypertensive effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 239000003087 receptor blocking agent Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
composição farmacêutica anti-hipertensiva a presente invenção fornece uma composição farmacêutica anti-hipertensiva contendo fimasaetan, um sal farmaceuticamente aceitável do mesmo, um solvagto do mesmo ou um hidrato do mesmo como um bloqueador dos recptores da angiotensina ii; e anlodipino, um isômero da mesma, um sal farmaceuticamente aceitável do mesmo, um solvato do mesmo ou um hidrato do mesmo como um bloqueador dos canais de cálcio.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0033856 | 2011-04-12 | ||
KR20110033856 | 2011-04-12 | ||
PCT/KR2011/005754 WO2012141385A1 (en) | 2011-04-12 | 2011-08-08 | Antihypertensive pharmaceutical composition |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112013025222A2 BR112013025222A2 (pt) | 2016-12-27 |
BR112013025222B1 BR112013025222B1 (pt) | 2020-03-17 |
BR112013025222B8 true BR112013025222B8 (pt) | 2020-05-05 |
Family
ID=47006840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013025222A BR112013025222B8 (pt) | 2011-04-12 | 2011-08-08 | composição farmacêutica anti-hipertensiva e uso da mesma |
Country Status (20)
Country | Link |
---|---|
US (1) | US8765776B2 (pt) |
JP (1) | JP5782178B2 (pt) |
AU (1) | AU2011365756B2 (pt) |
BR (1) | BR112013025222B8 (pt) |
CA (1) | CA2832758C (pt) |
CL (1) | CL2013002905A1 (pt) |
CO (1) | CO6821940A2 (pt) |
CR (1) | CR20130526A (pt) |
EA (1) | EA024096B1 (pt) |
EC (1) | ECSP13012962A (pt) |
GT (1) | GT201300241A (pt) |
MA (1) | MA35107B1 (pt) |
MX (1) | MX341450B (pt) |
MY (1) | MY160432A (pt) |
NI (1) | NI201300106A (pt) |
PE (1) | PE20141049A1 (pt) |
SG (1) | SG194162A1 (pt) |
UA (1) | UA110244C2 (pt) |
WO (1) | WO2012141385A1 (pt) |
ZA (1) | ZA201307593B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA110244C2 (en) | 2011-04-12 | 2015-12-10 | Boryung Pharm | Antihypertensive pharmaceutical composition |
KR101490329B1 (ko) * | 2012-10-12 | 2015-02-04 | 보령제약 주식회사 | 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물 |
KR20140096514A (ko) * | 2013-01-28 | 2014-08-06 | 보령제약 주식회사 | 암 예방 또는 치료용 조성물 |
JP6068765B2 (ja) * | 2013-03-14 | 2017-01-25 | ボリュン ファーマスーティカル カンパニー リミテッド | 薬学的複合製剤 |
KR20150041223A (ko) * | 2013-10-04 | 2015-04-16 | 보령제약 주식회사 | 피마살탄을 포함하는 허혈성 뇌질환 예방 또는 치료용 약학적 조성물 |
CN105395552A (zh) * | 2014-09-05 | 2016-03-16 | 南京华威医药科技开发有限公司 | 一种含非马沙坦及其盐的固体制剂 |
KR101545268B1 (ko) * | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
WO2017091041A1 (ko) * | 2015-11-26 | 2017-06-01 | 보령제약 주식회사 | 피마살탄의 신규 염 |
US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
CN112704667A (zh) * | 2021-02-24 | 2021-04-27 | 施慧达药业集团(吉林)有限公司 | 含苯磺酸左氨氯地平水合物的组合物及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
EP0733366B1 (en) | 1988-01-07 | 1998-04-01 | E.I. Du Pont De Nemours And Company | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics |
KR100300566B1 (ko) | 1994-09-17 | 2001-11-22 | 조생현 | 피리미디논유도체와그의제조방법및용도 |
KR19990081093A (ko) | 1998-04-25 | 1999-11-15 | 조생현 | 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법 |
CN1234357C (zh) | 1998-07-10 | 2006-01-04 | 诺瓦提斯公司 | 缬沙坦和钙通道阻断剂的抗超敏组合 |
FR2783422A1 (fr) | 1998-09-21 | 2000-03-24 | Sanofi Sa | Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire |
KR100617953B1 (ko) | 2000-03-23 | 2006-08-30 | 보령제약 주식회사 | 피리미디논 화합물 및 이의 염의 제조방법 |
EP1436283B1 (en) | 2001-09-21 | 2008-01-23 | Boryung Pharmaceutical Co., Ltd. | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof |
KR100521980B1 (ko) | 2002-10-10 | 2005-10-17 | 보령제약 주식회사 | 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법 |
ES2404939T3 (es) * | 2005-06-27 | 2013-05-29 | Daiichi Sankyo Company, Limited | Preparación farmacéutica que contiene un antagonista del receptor de la angiotensina II y un bloqueador de los canales de calcio |
KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
KR20100048137A (ko) | 2008-10-30 | 2010-05-11 | 현대약품 주식회사 | 혈압 강하용 약학 조성물 |
KR101058284B1 (ko) | 2010-01-22 | 2011-08-22 | 보령제약 주식회사 | 2-(2-n-부틸-4-히드록시-6-메틸-피리미딘-5-일)-N,N-디메틸아세트아미드의 신규한 제조방법 |
UA110244C2 (en) | 2011-04-12 | 2015-12-10 | Boryung Pharm | Antihypertensive pharmaceutical composition |
-
2011
- 2011-08-08 UA UAA201312969A patent/UA110244C2/ru unknown
- 2011-08-08 US US13/205,545 patent/US8765776B2/en active Active
- 2011-08-08 EA EA201370219A patent/EA024096B1/ru not_active IP Right Cessation
- 2011-08-08 AU AU2011365756A patent/AU2011365756B2/en not_active Ceased
- 2011-08-08 MY MYPI2013701917A patent/MY160432A/en unknown
- 2011-08-08 PE PE2013002274A patent/PE20141049A1/es active IP Right Grant
- 2011-08-08 BR BR112013025222A patent/BR112013025222B8/pt active IP Right Grant
- 2011-08-08 SG SG2013075585A patent/SG194162A1/en unknown
- 2011-08-08 CA CA2832758A patent/CA2832758C/en active Active
- 2011-08-08 WO PCT/KR2011/005754 patent/WO2012141385A1/en active Application Filing
- 2011-08-08 MX MX2013011879A patent/MX341450B/es active IP Right Grant
- 2011-08-08 JP JP2014505053A patent/JP5782178B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-08 CO CO13238680A patent/CO6821940A2/es not_active Application Discontinuation
- 2013-10-09 GT GT201300241A patent/GT201300241A/es unknown
- 2013-10-10 CL CL2013002905A patent/CL2013002905A1/es unknown
- 2013-10-10 CR CR20130526A patent/CR20130526A/es unknown
- 2013-10-10 EC ECSP13012962 patent/ECSP13012962A/es unknown
- 2013-10-11 NI NI201300106A patent/NI201300106A/es unknown
- 2013-10-11 ZA ZA2013/07593A patent/ZA201307593B/en unknown
- 2013-11-08 MA MA36404A patent/MA35107B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MX341450B (es) | 2016-08-19 |
BR112013025222A2 (pt) | 2016-12-27 |
CL2013002905A1 (es) | 2014-04-11 |
NI201300106A (es) | 2014-05-05 |
PE20141049A1 (es) | 2014-09-05 |
AU2011365756B2 (en) | 2015-07-30 |
MY160432A (en) | 2017-03-15 |
SG194162A1 (en) | 2013-11-29 |
JP5782178B2 (ja) | 2015-09-24 |
UA110244C2 (en) | 2015-12-10 |
EA201370219A1 (ru) | 2014-02-28 |
JP2014510785A (ja) | 2014-05-01 |
CO6821940A2 (es) | 2013-12-31 |
GT201300241A (es) | 2015-08-13 |
ECSP13012962A (es) | 2013-11-29 |
CR20130526A (es) | 2014-03-11 |
EA024096B1 (ru) | 2016-08-31 |
US20120264772A1 (en) | 2012-10-18 |
CA2832758C (en) | 2015-12-15 |
BR112013025222B1 (pt) | 2020-03-17 |
MA35107B1 (fr) | 2014-05-02 |
WO2012141385A1 (en) | 2012-10-18 |
MX2013011879A (es) | 2014-03-31 |
CA2832758A1 (en) | 2012-10-18 |
ZA201307593B (en) | 2015-04-29 |
AU2011365756A1 (en) | 2013-10-31 |
US8765776B2 (en) | 2014-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013025222B8 (pt) | composição farmacêutica anti-hipertensiva e uso da mesma | |
CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
CY1116645T1 (el) | Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch | |
UA122346C2 (uk) | ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ | |
PH12016500739A1 (en) | Inhibitors of the fibrolast growth factor receptor | |
EA021377B9 (ru) | Модуляторы толл-подобных рецепторов | |
EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
EA201290984A1 (ru) | Гелеобразные фармацевтические композиции, препятствующие злоупотреблению | |
BR112014025041B8 (pt) | Composição farmacêutica | |
PH12017501816A1 (en) | Azabensimidazoles and their use as amp a receptor modulators | |
BR112015019587A2 (pt) | combinações compreendendo compostos maba e corticosteroides | |
EA201490761A1 (ru) | R(+)-n-формилпропаргиламиноиндан | |
WO2013138568A8 (en) | Liver x receptor modulators | |
EA201070059A1 (ru) | Композиции, содержащие ингибиторы триптофангидроксилазы | |
CY1119525T1 (el) | Συνθεση 3-(5-αμινο-2-μεθυλ-4-οξοκιναζολιν-3(4η)-υλ)πιπε-ριδινο-2,6-διονης | |
CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
MX354818B (es) | Moduladores del receptor x del higado. | |
CL2013000069A1 (es) | Compuestos derivados de heterociclos fusionados, moduladores s1p; composicion farmaceutica; y uso en enfermedades neurodegenerativas. | |
EA201491517A1 (ru) | N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения | |
EA201492029A1 (ru) | N-этил-4-гидроксил-1-метил-5-(метил(2,3,4,5,6-пентагидроксигексил)амино)-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид | |
BR112013018781A2 (pt) | composto derivado de piridona, e, composição farmacêutica | |
EA201390603A1 (ru) | Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин | |
MX2016008406A (es) | Preparacion farmaceutica combinada que comprende el bloqueante del receptor de la angiotensina ii y el inhibidor de la hmg-coa reductasa. | |
EA201600166A1 (ru) | Производные пиперидина и азепина как модуляторы рецептора прокинетицина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2567 DE 17/03/2020 QUANTO AO ENDERECO. |